A股異動丨華人健康兩連跌累跌逾10% 遭股東阿里健康連續減持
華人健康(301408.SZ)現跌4.5%報元12.11,暫成交1.16億元,最新市值48.4億元;該股已連續2日下跌累跌逾10%。華人健康近日公佈,股東阿里健康通過集中競價交易及大宗交易的方式累計減持公司股份4,808,277股,佔公司總股本的比例爲1.20%,本次權益變動後,阿里健康持有公司股份25,241,096股,佔公司總股本的比例爲6.31%。華人健康昨日晚間又發公告稱,阿里健康通過集中競價交易及大宗交易的方式累計減持0.47%公司股份,本次權益變動後,阿里健康持有公司股份23,371,096股,佔公司總股本的比例爲5.84%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.